Ticker Details
TG Therapeutics, Inc. TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
IPO Date:	June 1, 2010
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$9.04B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.53 | 3.43%
Avg Daily Range (30 D):	$1.28 | 2.71%
Avg Daily Range (90 D):	$0.93 | 2.36%

Institutional Daily Volume
Avg Daily Volume:	1.35M
Avg Daily Volume (30 D):	1.95M
Avg Daily Volume (90 D):	1.8M

Trade Size
Avg Trade Size (Sh.):	114
Avg Trade Size (Sh.) (30 D):	65
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	6,232
Avg Institutional Trade:	$3.02M
Avg Institutional Trade (30 D):	$6.72M
Avg Institutional Trade (90 D):	$5.53M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.63M
Avg Closing Trade (30 D):	$30.28M
Avg Closing Trade (90 D):	$17.24M
Avg Closing Volume:	269.59K

News

Feb 8, 2026 @ 9:17 PM TG Therapeutics Announces Collaboration with Chris... Source: Tg Therapeutics, Inc.

Jan 14, 2026 @ 1:36 PM Stock Market Today: S&P 500, Dow Jones, Nasdaq 100... Source: Rishabh Mishra

Nov 10, 2025 @ 9:00 PM TG Therapeutics to Participate in the TD Cowen Imm... Source: Tg Therapeutics, Inc.

Aug 4, 2025 @ 4:23 PM TG Therapeutics Q2 Revenue Up 91% Source: Jesterai

May 5, 2025 @ 11:00 AM TG Therapeutics Reports First Quarter 2025 Financi... Source: N/A

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$3.22	$.14	$.2
Diluted EPS	$2.87	$.12	$.15
Revenue	$700.35M	$204.92M	$192.57M
Gross Profit	$581.67M	$171.41M	$154.43M
Net Income / Loss	$461.9M	$19.78M	$23.04M
Operating Income / Loss	$149.5M	$34.8M	$50.49M
Cost of Revenue	$118.68M	$33.51M	$38.14M
Net Cash Flow	$310.12M	$363.07M	$5.08M
PE Ratio

Splits
Apr 30, 2012	5:281
Jul 14, 2011	1:50
Sep 25, 2003	1:5